Boston Scientific Corporation (0HOY.L)
| Previous close | 76.28 |
| Open | 76.80 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 75.77 - 76.80 |
| 52-week range | 47.37 - 76.80 |
| Volume | |
| Avg. volume | 26,833 |
| Market cap | 105.488B |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | 1.44 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Boston Scientific Announces Conference Call Discussing Second Quarter 2024 Results
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2024, on Wednesday, July 24, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the second quarter on July 24 prior to the conference call.
- GlobeNewswire
Silk Road Medical Announces Definitive Agreement to be Acquired by Boston Scientific
Boston Scientific to acquire Silk Road Medical for $27.50 per share in cash SUNNYVALE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (“Silk Road”) (NASDAQ:SILK), a leading minimally invasive medical device company for carotid artery procedures, announced today it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (“Boston Scientific”) (NYSE: BSX), a global medical technology leader, for $27.50 in cash per share, representing an equity valu
- PR Newswire
Boston Scientific Announces Agreement to Acquire Silk Road Medical, Inc.
Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). The purchase price is $27.50 per share, reflecting an enterprise value of approximately $1.16 billion.i
